title: Reply to 'how does weight influence tenofovir disoproxil-fumarate induced renal function decline?'.
authors.affiliation: aAIDS Clinical Center, National Center for Global Health and Medicine, Tokyo bCenter for AIDS Research, Kumamoto University, Kumamoto cBiostatistics Section, Department of Clinical Research and Informatics, Clinical Science Center, National Center for Global Health and Medicine, Tokyo, Japan.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Nishijima
authors.forename: Yohei
authors.initials: Y
authors.lastname: Kawasaki
authors.forename: Noriko
authors.initials: N
authors.lastname: Tanaka
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Gatanaga
authors.forename: Shinichi
authors.initials: S
authors.lastname: Oka
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives*; D019380:Anti-HIV Agents / Q000009:adverse effects*; D001835:Body Weight; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects*; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D063065:Organophosphonates / Q000009:adverse effects*; D051437:Renal Insufficiency / Q000139:chemically induced*
chemical_list: D019380:Anti-HIV Agents; D063065:Organophosphonates; D000225:Adenine